


ORIGINAL RESEARCH

Enteroendocrine Progenitor Cell–Enriched miR-7 Regulates Intestinal Epithelial Proliferation in an *Xiap*-Dependent Manner

08 Ajeet P. Singh,^{1,*} Yu-Han Hung,^{1,*} Michael T. Shanahan,¹ Matt Kanke,¹ Alessandro Bonfini,² Michael K. Dame,³ Mandy Biraud,⁴ Bailey C. E. Peck,⁵ Oyebola O. Oyesola,⁶ John M. Freund,⁷ Rebecca L. Cubitt,¹ Ennessa G. Curry,⁸ Liara M. Gonzalez,⁷ Gavin A. Bewick,⁹ Elia D. Tait-Wojno,⁶ Natasza A. Kurpios,¹⁰ Shengli Ding,⁸ Jason R. Spence,³ Christopher M. Dekaney,⁴ Nicolas Buchon,² and Praveen Sethupathy¹

¹Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York; ²Cornell Institute of Host-Microbe Interactions and Disease, Department of Entomology, Cornell University, New York; ³Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan; ⁴Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina; ⁵Department of Surgery, University of Michigan, Ann Arbor, Michigan; ⁶Baker Institute of Animal Health and Department of Microbiology and Immunology, Cornell University, Ithaca, New York; ⁷Department of Clinical Sciences, North Carolina State University, Raleigh, North Carolina; ⁸Department of Cell Biology and Physiology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina; ⁹Diabetes Research Group, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; and ¹⁰Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, New York



SUMMARY

It was recently shown that progenitors of enteroendocrine cells contribute to intestinal epithelial growth, but the underlying mechanisms remain poorly understood. We uncover the role of enteroendocrine cell–progenitor enriched microRNA 7 in regulating intestinal epithelial growth via *Xiap* and *Egfr* signaling.

BACKGROUND & AIMS: The enteroendocrine cell (EEC) lineage is important for intestinal homeostasis. It was recently shown that EEC progenitors contribute to intestinal epithelial growth and renewal, but the underlying mechanisms remain poorly understood. MicroRNAs are underexplored along the entire EEC lineage trajectory, and comparatively little is known about their contributions to intestinal homeostasis.

METHODS: We leverage unbiased sequencing and eight different mouse models and sorting methods to identify microRNAs enriched along the EEC lineage trajectory. We further characterize the functional role of EEC progenitor-enriched miRNA, miR-7, by *in vivo* dietary study as well as *ex vivo* enteroid in mice.

RESULTS: First, we demonstrate that miR-7 is highly enriched across the entire EEC lineage trajectory and is the most enriched miRNA in EEC progenitors relative to *Lgr5*+ intestinal stem cells. Next, we show *in vivo* that in EEC progenitors miR-7 is dramatically suppressed under dietary conditions that favor crypt division and suppress EEC abundance. We then demonstrate by functional assays in mouse enteroids that miR-7 exerts robust control of growth, as determined by budding (proxy for crypt division), EdU and PH3 staining, and likely regulates EEC abundance also. Finally, we show by single-cell RNA sequencing analysis that miR-7 regulates *Xiap* in progenitor/stem cells and we demonstrate in enteroids that the effects of

117 miR-7 on mouse enteroid growth depend in part on Xiap and
118 Egfr signaling.

119
120 **CONCLUSIONS:** This study demonstrates for the first time that
121 EEC progenitor cell-enriched miR-7 is altered by dietary per-
122 turbations and that it regulates growth in enteroids via intact
123 Xiap and Egfr signaling. (*Cell Mol Gastroenterol Hepatol*
124 2019;■:■-■; <https://doi.org/10.1016/j.jcmgh.2019.11.001>)

125
126 **Keywords:** miR-7; Enteroendocrine Lineage; Small Intestine;
127 Enteroid; Proliferation.

128
129 **T**he intestinal epithelium is the most rapidly renew-
130 ing tissue in the body. This feature is driven by
131 crypt-based intestinal stem cells (ISCs), which exhibit self-
132 renewal properties and are responsible for giving rise to
133 all of the differentiated cell types in the absorptive (enter-
134 ocyte) and secretory lineages (Paneth cell, tuft cell, goblet
135 cell and enteroendocrine cells [EECs]).¹ So far, 2 distinct
136 populations of ISCs have been defined: actively cycling ISCs
137 (aISCs) at the base of the crypt and reserve/slowly cycling
138 ISCs (rISCs) at the +4 position from the crypt base.² More
139 recently, though, several other intermediate cell pop-
140 ulations, notably progenitors of EECs, have been shown to
141 participate in the control of crypt behavior under certain
142 conditions.^{3,4}

143 EEC progenitors, which were thought to be fully
144 committed to EEC differentiation, have recently been
145 recognized to have proliferative potential and thereby
146 contribute to the control of cell proliferation, crypt growth,
147 and related behaviors.^{3,4} A recent study identified Prospero
148 homeobox protein 1 (Prox1) as a novel marker labeling
149 intermediates in the EEC lineage and demonstrated that
150 sorted Prox1+ cells are sufficient for establishing enteroids
151 ex vivo. Despite this advance, much remains unknown about
152 the mechanisms that control EEC lineage behavior. It is of
153 substantial interest to map the molecular landscape of the
154 cells in the entire EEC lineage trajectory to define the
155 mechanisms that control intestinal epithelial cell prolifera-
156 tion, crypt division or growth, or EEC differentiation.

157 MicroRNAs (miRNAs) are prominent posttranscriptional
158 regulators of growth and cell fate decisions in many organ
159 systems and disease models^{5,6}; however, very little is
160 known about their role in the regulation of intestinal crypt
161 behavior. In fact, it is not even known which miRNAs are
162 expressed along the entire EEC lineage trajectory, particu-
163 larly the EEC progenitors or whether they are sensitive to
164 perturbations that influence crypt division or EEC differ-
165 entiation.⁷ In this study, using 8 different reporter mice and
166 several sorting methods, we profile miRNAs in several lin-
167 eages of the small intestinal epithelium, identify microRNA 7
168 (miR-7) as the most highly enriched miRNA in EEC pro-
169 genitors relative to Lgr5+ stem cells, show that miR-7 in
170 EEC progenitors is among the most sensitive miRNAs to
171 dietary conditions that favor crypt growth and reduced EEC
172 abundance, and demonstrate through ex vivo functional
173 studies and single cell analyses that miR-7 controls enteroid
174 growth in part by regulation of *Xiap*.
175

176 Results

177 *MiR-7 Is the Most Enriched miRNA in EEC* 178 *Progenitors Relative to Lgr5+ Stem Cells*

179 In this study, we defined the EEC lineage trajectory as
180 the following: (1) Lgr5+ aISCs, (2) Sox9-Low cells and
181 Hopx+ cells that exhibit features of the EEC lineage, (3)
182 Prox1+ EEC progenitors, (4) Sox9-High and lower side
183 population (LSP) cells that represent a mixed population of
184 rISCs and mature EECs, and (5) Pyy+ cells that represent
185 mature EECs. To define the miRNA landscape across the EEC
186 lineage trajectory, we first investigated Sox9-EGFP reporter
187 mice (Figure 1A). From the jejunal crypts of the Sox9-EGFP
188 mice, we sorted and performed small RNA sequencing
189 (RNA-seq) analysis on 4 different epithelial cell populations
190 enriched in enterocytes (Sox9-Negative), stem cells or EEC
191 progenitors (Sox9-Low) (hereafter referred to as EEC pro-
192 genitors), transit amplifying cells (Sox9-Sublow), and
193 mature EECs (Sox9-High), and demonstrated that each
194 fraction is enriched for the expected markers (Figure 1B).
195 We then focused our analysis on the cell populations in the
196 EEC lineage trajectory, Sox9-Low and Sox9-High. The small
197 RNA-seq analysis identified a total of 187 miRNAs in these 2
198 populations. Of these, we found that only 8 miRNAs are
199 enriched (>5-fold) in mature EECs (class A), 2 in stem or
200 EEC progenitors (class B), and 14 in both (class C) relative
201 to unsorted intestinal epithelial cells (Table 1). Class A
202 miRNAs represent candidate regulators of mature EEC
203 function, class B miRNAs represent candidate regulators of
204 EEC progenitor cell behavior, and class C miRNAs represent
205 candidate regulators of both mature EEC function and EEC
206 progenitor cell behavior. Notably, class C miRNAs include
207 miR-7b, which has been previously extensively studied in
208 the context of endocrine pancreatic development and
209 function.⁸⁻¹⁵ miR-7 was also shown to be enriched in a
210 specific subtype of mature EECs and cholecystokinin-
211 producing EECs,¹⁶ and also in enterochromaffin cell-
212 derived tumors¹⁷; however, importantly, the expression
213 pattern of miR-7 (or any other miRNA) across the entire
214 EEC lineage trajectory has never before been reported.

215 Next, from the jejunal crypts of Lgr5-EGFP, Prox1-EGFP,
216 and Hopx-CreERT2;Rosa26-tdTomato reporter mice
217 (Figure 1A), we sorted Lgr5+, Prox1+, and Hopx+ cells,
218 respectively, and performed small RNA-seq to define
219

220
221
222 *Authors contributed equally.

223 **Abbreviations used in this paper:** aISC, actively cycling intestinal stem
224 cell; BSA, bovine serum albumin; EdU, 5-ethynyl-2'-deoxyuridine; EEC,
225 enteroendocrine cell; FACS, fluorescence-activated cell sorting; HFD,
226 high-fat diet; IAP, inhibitor of apoptosis protein; ISC, intestinal stem
227 cell; LFD, low-fat diet; LNA, locked nucleic acid; LNA-7, locked nucleic
228 acid inhibitors against microRNA 7; LNA-scr, locked nucleic acid
229 scramble control; LSP, lower side population; miR-7, microRNA 7;
230 miRNA, microRNA; rISC, reserve/slowly cycling intestinal stem cell;
231 PBS, phosphate-buffered saline; RNA-seq, RNA sequencing; RT-
232 qPCR, reverse transcriptase quantitative polymerase chain reaction;
233 USP, upper side population.

234 © 2019 The Authors. Published by Elsevier Inc. on behalf of the AGA
235 Institute. This is an open access article under the CC BY-NC-ND
236 license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

237 2352-345X

238 <https://doi.org/10.1016/j.jcmgh.2019.11.001>




Figure 1. MicroRNA-7 is highly enriched in the enteroendocrine (EEC) lineage trajectory. (A) Schematic diagram of different sorted cell populations representing specific cell lineages in the small intestine. (B) Level of expression (RNA-seq) of specific marker genes in each of the Sox9-Low (n = 4), Sox9-High (n = 3), and Sox9-Negative (n = 4) populations of cells. (C) Hierarchical clustering analysis based on the expression profiles of the top 50 most variable miRNAs across the different sorted cell populations shown in the heat map (Sox9-Low, n = 3; Sox9-High, n = 3; Sox9-Negative, n = 3; Sox9-Sublow, n = 3; Sox9-Unsorted, n = 2; Lgr5-High, n = 2; Hopx+, n = 4; Prox1+, n = 3). (D) MiR-7a/b expression in the EEC lineage vs non-EEC absorptive lineage. Similar data for miR-194 and miR-215 provided for sake of comparison. (E) RT-qPCR data showing enrichment of *Hopx* and miR-7 in Hopx+ cells (n = 4) relative to Hopx- cells (n = 4). (F) RT-qPCR data showing enrichment of miR-7, *Lgr5*, and *Chga* in LSP (n = 2) relative to USP (n = 2) and Lgr5+ cells (n = 2). (G) RT-qPCR data showing enrichment of *Prox1*, miR-7, and *Chga* in Prox1+ cells (n = 3) compared with Prox1- cells (n = 3). (H) Scatter plot showing abundance (y-axis) and enrichment (x-axis) of all detected miRNAs in Prox1+ cells (n = 3) relative to Prox1- cells (n = 3). MiRNAs above expression of 1000 reads per million mapped to miRNAs and 5-fold enrichment are shown in red (n = 10). Among these, miR-7b is highlighted in blue. (I) Fold-difference in expression of the 10 miRNAs highlighted in panel F in Prox1+ cells (n = 3) relative to Lgr5+ cells (n = 2) highlights miR-7 (blue) as a robust EEC progenitor cell enriched miRNA. (J) The left panel shows RT-qPCR data showing enrichment of *Lyz1* (marker of Paneth cells) in Defa6+ (n = 4) relative to Defa6- cells (n = 4). The middle panel shows RT-qPCR data showing enrichment of *Dclk1* (marker of tuft cells) in Siglec+/CD45-/EpCam+ cells (n = 2) relative to unsorted cells (n = 2). The right panel shows RT-qPCR data showing miR-7 enrichment in EECs (Sox9-High; n = 2) compared with Paneth and tuft cells. * $P < .05$, ** $P < .01$, *** $P < .001$ by 2-tailed Student *t* test. RQV, relative quantitative value.

235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293

294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352

web 4C/FPO

Table 1. Small RNA-seq Profiling Followed by Enrichment Analysis of miRNAs in Stem/EEC Progenitors (Sox9-Low, n = 3) and in Mature EECs (Sox9-High, n = 3) Relative to Unsorted Intestinal Epithelial Cells (n = 2)

Class A miRNAs Enriched in Mature EEC (Sox9-High)	Class B miRNAs Enriched in Progenitor EEC (Sox9-Low)	Class C miRNAs Enriched in Both Mature and Progenitor EECs
miR-139-3p	miR-181c-3p	let-7e-5p
miR-182-5p	miR-181d-5p	miR-1224-5p
miR-182-5p_+_1		miR-125a-5p
miR-183-5p		miR-132-3p
miR-183-5p_+_1		miR-184-3p
miR-328-3p		miR-375-3p
miR-672-5p		miR-375-3p_-_1
miR-744-5p		miR-375-3p_+_1
		miR-375-3p_+_2
		miR-7a-2-3p
		miR-7b-5p
		miR-7b-5p_+_1
		miR-92b-3p
		miR-99b-5p

Only miRNAs that have an average reads per million mapped to miRNAs (reads per million mapped to miRNAs) >100 in either Sox9-Low or Sox9-High and have <2-fold enrichment in Sox9-Sublow (transit-amplifying cells) and Sox9-Negative (enterocytes) are shown. EEC, EEC, enteroendocrine cell; miRNA, microRNA; RNA-seq, RNA sequencing.

miRNA profiles in each population (Figure 1C). We found that the level of expression of miR-7a and miR-7b increases steadily along the EEC trajectory from Lgr5+ aISCs to Sox9-Low EEC progenitors to Sox9-High mature EECs, in contrast to other miRNAs such as miR-194 and miR-215, which are depleted in the EEC lineage and enriched in the non-EEC, absorptive lineage (Sox9-Sublow and Sox9-Negative) (Figure 1D). We also found by quantitative polymerase chain reaction (qPCR) that miR-7 is significantly enriched in Hopx+ cells (Figure 1E), which have been shown previously to exhibit molecular features of EEC progenitors.¹⁸ Moreover, through small RNA-seq analysis, we found that miR-7b is one of the top 3 miRNAs to be significantly enriched (>5-fold enrichment based on expression as measured by reads per million mapped to miRNAs and $P < .05$ by 2-tailed Student *t* test) in Hopx+ cells relative to Hopx- cells, further underscoring the potential importance of miR-7b in EEC progenitors.

To validate that the miR-7 family is enriched in EEC progenitors, we next performed side population sorting of the intestinal epithelium and isolated the LSP and upper side population (USP) of cells, which correspond to rISCs and aISCs, respectively (Figure 1A). Consistent with the notion of overlapping identity between rISCs and cell populations in the EEC lineage,¹⁸ we found that LSP cells exhibit molecular features of mature EECs and EEC progenitors,

including expression of *Chga* (Figure 1F), and are depleted for markers of aISCs, including *Lgr5* (Figure 1F). RT-qPCR analysis showed that miR-7 is significantly enriched in LSP relative to both USP and Lgr5+ cells (Figure 1F), confirming miR-7 enrichment in cells with EEC progenitor features.

To cement the finding of miR-7 enrichment in EEC progenitors, we next turned our attention to the Prox1+ cells sorted from the intestinal epithelium of Prox1-EGFP reporter mice (Figure 1A, C). Prox1 was recently shown to mark intestinal secretory progenitors with the capacity to either differentiate to mature EECs or exhibit proliferative stem cell-like activity (4), and our small RNA-seq analysis showed that the miRNA profile of intestinal epithelial Prox1+ cells most closely resembles that of Hopx+ cells (rISCs/EEC progenitors) and Sox9-Low cells (EEC progenitors) (Figure 1C). We first demonstrated by qPCR that the traditional EEC lineage marker, *Chga*, and miR-7 are significantly enriched in Prox1+ cells (Figure 1G). Then, we analyzed the small RNA-seq data and found that only 10 miRNAs are >5-fold enriched in Prox1+ cells relative to Prox1- cells (Figure 1H). Several of these, including miR-7b, overlap with the class C miRNAs defined in Table 1. Notably, among these 10 miRNAs, we found that miR-7b is by far the most dramatically enriched (~41-fold) in Prox1+ EEC progenitors relative to Lgr5+ aISCs (Figure 1I).

Prox1+ progenitor cells are thought to give rise not only to mature EECs but also to differentiated tuft cells. To determine whether miR-7 is truly enriched along the EEC lineage trajectory, or also highly abundant in tuft cells, we next measured miR-7 in mouse jejunal tuft cells (Epcam+/Sicleg+/Cd45- cells sorted from wild-type C57BL/6J mice), which are highly enriched as expected for the tuft cell marker *Dclk1* (Figure 1J). This analysis revealed that miR-7 is >350-fold enriched in Sox-9 High EECs relative to *Dclk1*+ tuft cells (Figure 1J). As a control, we also included Lyz1+ Paneth cells sorted from the Defa6-Cre;tdTomato line (Figure 1J), and demonstrated that miR-7 is indeed significantly depleted in these cells relative to Sox9-High EECs (Figure 1J). As additional validation, we sorted Pyy+ EECs from the jejunum of Pyy-EGFP reporter mice and found that miR-7 is >600-fold more highly expressed in Pyy+ cells than in tuft cells (data not shown). These findings provide strong support for the enrichment of miR-7 along the entire EEC lineage trajectory.


Taken together, these data define a clear EEC lineage trajectory (from Lgr5+ aISCs to mature EECs) miRNA signature for the first time and reveal that miR-7 is the most enriched miRNA in EEC progenitors compared with Lgr5+ aISCs.

MiR-7 Expression in EEC Progenitors, Not Mature EECs, Is Suppressed Under Conditions of Increased Intestinal Crypt Division and Reduced EEC Abundance

Several different types of environmental perturbations, including dietary modifications, have been reported to alter both crypt growth and EEC differentiation.^{19,20} For example, a high-fat diet (HFD) robustly increases intestinal crypt

471 division (indicative of enhanced proliferation) and decreases EEC abundance in mice compared with a low-fat
 472 diet (LFD).²⁰ Our previously described expression analysis
 473 demonstrated that miR-7 is highly expressed in Sox9-Low
 474 EEC progenitor cells (Figure 1D), which exhibit both pro-
 475 liferative and differentiative capacity, but relatively low
 476 expressed in Lgr5+ aISCs (Figure 1D). If miR-7 is critical to
 477 the control of crypt division or EEC abundance, we reasoned
 478 that it may be modulated by HFD. To determine whether

miR-7 is significantly altered by HFD, we performed a HFD
 530 study for 16 weeks, identical to the one previously
 531 described in Mah et al.²⁰ First, we confirmed that HFD-fed
 532 mice exhibit a significant increase relative to LFD-fed mice
 533 in body weight as expected (58.8% increase; $P = 1.271e-9$;
 534 LFD, $n = 8$; HFD, $n = 9$). Next, we showed by histo-
 535 morphometry that crypt density, a marker of the rate of
 536 crypt division, is significantly elevated in the jejunum of
 537 HFD-fed mice (Figure 2A). We also observed a significant



480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529

530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588

increase in the number of 5-ethynyl-2'-deoxyuridine-positive (EdU+) cells/crypt (proliferating cells) in jejunal crypts from HFD-fed mice (Figure 2B). Finally, we demonstrated by immunofluorescence that HFD-fed animals exhibit significantly lower Chga+ cell/villus count, indicative of reduced EEC number (Figure 2C).

To determine whether the EEC progenitor enriched miR-7 is associated with this hyperproliferative phenotype, we next performed small RNA-seq in sorted Sox9-Low cells (EEC progenitors) from the jejunal epithelial tissue of both LFD- and HFD-fed mice (Figure 2D). Principal component analysis on miRNA profiles showed clear separation of LFD- and HFD-fed mice (Figure 2E) and differential miRNA expression analysis identified 15 miRNAs (7 up, 8 down) in Sox9-Low cells altered by more than 2-fold (Figure 2F). Notably, the downregulated group of miRNAs includes the EEC lineage-enriched miR-7b (Figure 2G). In addition, the downregulation of miR-7b by the dietary perturbation appears specific to EEC progenitors, as it is downregulated by HFD only in Sox9-Low (EEC progenitors) but not in Sox9-High (mature EECs) (Figure 2H). This finding indicates that miR-7 is suppressed in EEC progenitors under physiologic conditions that promote crypt division and reduce EEC abundance in the intestinal epithelium.

Genes Upregulated in EEC Progenitors Under Conditions of Increased Crypt Division Are Enriched for Predicted Targets of miR-7

Given that HFD alters miR-7 in Sox9-Low (EEC progenitors) but not Sox9-High cells (mature EECs) (Figure 2G), we next performed RNA-seq in sorted Sox9-Low cells from the jejunal epithelial tissue of both LFD- and HFD-fed mice (Figure 2D). Principal component analysis on gene expression profiles showed clear separation of LFD- and HFD-fed mice (Figure 2I) and differential expression analysis identified nearly 1700 significantly (adjusted $P < .05$) altered

genes (410 up, 1279 down) (Figure 2J). After multiple testing correction, the genes upregulated by HFD are most significantly enriched in the Ppar δ transcriptional network (Enrichr KEGG, $P = 9.89e-6$), including genes involved in fatty acid oxidation (Figure 2K), which is consistent with the finding from a recent study in the colon after a much longer HFD regimen.²¹ In the HFD condition, we also found that several genes involved in crypt division and enterocyte differentiation are significantly upregulated whereas genes that encode transcription factors that drive EEC maturation are significantly downregulated (Figure 2K), which is in line with the observed cellular phenotypes (Figure 2A–2C). Using the bioinformatic tool miRhub,²² we showed that upregulated genes are significantly enriched for predicted target sites of only 1 downregulated miRNA, miR-7 (Figure 2L). This shows that genes upregulated in EEC progenitors under conditions of increased intestinal epithelial proliferation are overrepresented for predicted targets of miR-7. Notably, among the upregulated genes is X-linked inhibitor of apoptosis (*Xiap*) (Figure 2M), which encodes a protein that promotes crypt survival and growth. While *Xiap* has been reported as a direct target of miR-7 in the context of cervical cancer,²³ it has never been reported previously in the small intestine. Indeed, the levels of *Xiap* and miR-7b are strongly inversely correlated in EEC progenitors across LFD- and HFD-fed mice (Figure 2N).

MiR-7 Controls Intestinal Epithelial Growth


The previous findings, most notably that miR-7 in EEC progenitors is strongly suppressed under conditions of increased crypt division and that the genes upregulated during increased crypt division are enriched for miR-7 predicted targets, led us to hypothesize that miR-7 may regulate crypt division. To test this hypothesis, we established 3-dimensional enteroids from jejunal crypts of C57BL/6/J mice and treated them with locked nucleic acid inhibitors against miR-7 (LNA-7) and compared with

Figure 2. (See previous page). MiR-7 expression is suppressed and predicted miR-7 targets are elevated in EEC progenitors under conditions of increased intestinal crypt division and reduced EEC abundance. (A) Representative hematoxylin and eosin images and crypt density quantification of mid-jejunum from HFD-fed ($n = 9$) and LFD-fed ($n = 8$) mix of Lgr5-EGFP reporter mice and naïve C57BL/6 wild-type (WT) mice. Bar = 100 μ m. (B) Representative images of tissue sections stained with Hoechst (blue) and EdU (red) and quantification of EdU+ cells per crypt from HFD-fed ($n = 8$) and LFD-fed ($n = 7$) Lgr5-EGFP reporter mice and naïve C57BL/6 WT mice. (C) Representative images of tissue sections stained with Chga and quantification of Chga+ cells per villi (normalized by villi height) from HFD-fed ($n = 7$) and LFD-fed ($n = 4$) mix of Lgr5-EGFP reporter mice and C57BL/6 naïve WT mice. (D) Schematic of experimental workflow using Sox9-EGFP reporter mice. (E) Principal component analysis plot of small RNA-seq data of Sox9-Low cells from HFD-fed and LFD-fed Sox9-EGFP reporter mice. (F) Volcano plot of differentially expressed miRNAs in HFD-fed relative to LFD-fed Sox9-EGFP reporter mice (dashed lines represent fold-change > 2). (G) miRNAs that are significantly ($P < .05$) upregulated or downregulated in jejunal Sox9-Low sorted cells from HFD-fed relative to LFD-fed mice. Red and blue bars highlight miRNAs with >2 -fold change up or down in HFD-fed relative to LFD-fed mice, respectively. (H) Expression level of miR-7b (small RNA-seq) in Sox9-Low and Sox9-High cells from HFD-fed and LFD-fed Sox9-EGFP mice. (I) Principal component analysis plot of RNA-seq data of Sox9-Low cells from HFD-fed and LFD-fed mice. (J) Volcano plot of differentially expressed genes in HFD-fed relative to LFD-fed Sox9-EGFP reporter mice (dashed line represents adjusted $P < .05$). (K) Heatmap showing changes in genes involved in proliferation, EEC differentiation, and enterocyte differentiation of jejunal Sox9-Low cells of HFD-fed relative to LFD-fed mice. (L) Enrichment analysis of miRNA target sites (using the Monte Carlo simulation tool miRhub) in genes upregulated in response to HFD (dashed line represents $P < .05$). Only miRNAs downregulated greater than 2-fold in Sox9-Low cells from HFD-fed relative to LFD-fed mice are included in the analysis. (M) Sequencing data showing upregulation of miR-7 target gene *Xiap* in Sox9-Low cells from HFD-fed relative to LFD-fed mice. (N) Inverse correlation between expression level of miR-7b and *Xiap* among the HFD-fed and LFD-fed Sox9-EGFP reporter mice. All figure panels from panel E onward correspond to data from $n = 4$ HFD-fed and $n = 4$ LFD-fed Sox9-EGFP reporter mice. * $P < .05$, ** $P < .01$ by 2-tailed Student *t* test.

707 treatment with LNA-scramble control (LNA-scr) (Figure 3A).
 708 RT-qPCR analysis showed that treatment with LNA-7 led to
 709 a robust suppression (~55-fold) of the miR-7 family in
 710 enteroids (Figure 3B). Also, small RNA-seq analysis of LNA-
 711 7-treated enteroids revealed that miR-7 is suppressed by
 712 many orders of magnitude more than any other miRNA
 713 (Figure 3C, Table 2), demonstrating the specificity of the
 714 effects of LNA-7 on miR-7 expression.

715 Brightfield imaging showed that treatment with LNA-7
 716 (miR-7 loss-of-function) significantly increases enteroid
 717 budding, which is an *ex vivo* proxy for crypt division,²⁴
 718 relative to LNA-scr and mock (no treatment) controls
 719

(Figure 3D and 3E). We also confirmed this result in porcine
 766 enteroids (Figure 3F). Furthermore, we demonstrated that
 767 LNA-7 treatment dramatically increases EdU+ cells/enteroid
 768 (Figure 3G) and PH3+ cells/enteroid (Figure 3G and
 769 3H). Next, we performed complementary gain-of-function
 770 studies in mouse enteroids using miR-7 mimics. Our results
 771 showed that overexpression of miR-7 (Figure 3J)
 772 suppresses budding (Figure 3J and 3K) and leads to a
 773 reduction in PH3+ cells/enteroid (Figure 3J-3L), which is
 774 the opposite of what occurs upon inhibition of miR-7. These
 775 studies together demonstrate the functional role of miR-7 in
 776 the control of enteroid budding.
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824



825 *MiR-7 Controls Intestinal Epithelial Proliferation in* 826 *Drosophila Midgut In Vivo*

827 To determine whether this function of miR-7 is
828 conserved beyond mammals, we turned to the fruit fly
829 model (Figure 4A). We first demonstrated that miR-7 is the
830 most significantly reduced miRNA in the *Drosophila mela-*
831 *nogaster* midgut during the well-documented hyper-
832 proliferative response to infection by *Erwinia carotovora*
833 *carotovora* 15 (Ecc15) (Figure 4B and 4C).²⁵ To study miR-7
834 function specifically in proliferating intestinal epithelial
835 cells, we overexpressed miR-7 in *esg+* cells of the midgut,
836 which represent the stem or progenitor populations. We
837 found that the number of PH3+ (proliferating) cells is
838 dramatically reduced upon miR-7 overexpression in the
839 background of Ecc15 infection compared with control
840 (Figure 4D, E), which demonstrates that miR-7 down-
841 regulation is required for the hyperproliferative response to
842 bacterial insult and that miR-7 is a key regulator of
843 epithelial proliferative capacity in the midgut. While our
844 focus is on mammalian miR-7, and while there are notable
845 differences between fruit fly and mammalian gut tissue (eg,
846 lack of well-established EEC progenitors in the fruit fly gut),
847 the results from the *Drosophila* experiments convey a
848 remarkable evolutionary conservation of miR-7 function in
849 the intestinal epithelium.

851 *MiR-7 Control of Enteroid Budding Is Dependent* 852 *on Intact Xiap*

853 As mentioned previously, *Xiap* encodes a protein that
854 promotes cell survival and growth, and it is an established
855 direct target of miR-7 by 3' UTR reporter gene assays in a
856 cancer cell context.²³ However, the functional relevance of
857 the miR-7:*Xiap* regulatory relationship has not been exam-
858 ined in a noncancer context and definitely not in intestinal
859 epithelial growth. To determine whether miR-7 regulates
860 *Xiap* in enteroids, and to determine whether this regulation
861 takes place in proliferating cells (stem or progenitor cells),
862

884 we performed single-cell RNA-seq in mouse enteroids
885 treated with either LNA-scr or LNA-7. We sequenced just
886 enough cells to discern 3 clusters of different cell types,
887 progenitor/stem, Paneth, and enterocyte (Figure 5A). These
888 cell clusters are enriched for markers that are known to be
889 associated with each cell type (Figure 5B and 5C). Notably,
890 the signal for markers of proliferation increased in the
891 progenitor/stem population after treatment with LNA-7
892 (Figure 5C). Next, we focused on *Xiap* and found that its
893 average level across all cells is significantly elevated by
894 treatment with LNA-7 relative to LNA-scr (Figure 5D).
895 Moreover, the percentage of *Xiap*+ progenitor cells is ~2-
896 fold increased by LNA-7 (~21%) relative to
897 LNA-scramble (~10%) (Figure 5E). In progenitor/stem
898 cells, the fold-increase of *Xiap*+ cells after LNA-7 treatment
899 is even greater (~3-fold) (Figure 5F). These results suggest
900 that more progenitor or stem cells express *Xiap*, and at
901 higher levels, after LNA-7 treatment. Although mouse
902 enteroids comprise many differentiated cell types, most of
903 which do not robustly express miR-7, human enteroids tend
904 to retain a more stem or progenitor state in culture.²⁶
905 Therefore, to test miR-7 regulation of *XIAP*, we treated hu-
906 man enteroids with LNA-7, which led to dramatic suppres-
907 sion of miR-7 and a significant increase in *XIAP* (Figure 5G).

908 To determine whether miR-7 control of enteroid growth
909 is mediated in part by regulation of *Xiap*, we examined the
910 effect of LNA-7 in mouse enteroids in the context of *Xiap*
911 suppression. Treatment of enteroids with GDC0152, an *Xiap*
912 inhibitor, effectively reduced *Xiap*+ cells per enteroid
913 (Figure 5H) and suppresses the budding phenotype
914 (Figure 5I). We then showed that treatment with GDC0152
915 significantly blunts the effects of LNA-7 on *Xiap*+ cells/
916 enteroid (Figure 5J), budding (Figure 5K), and PH3+ cells/
917 enteroid (Figure 5L). These results convey that the effects of
918 miR-7 on enteroid growth are mediated at least in part
919 through regulation of *Xiap*.

920 *Xiap* is known to promote *Egfr*.²⁷ To evaluate further the
921 dependency on *Egfr*, we next tested the effect of LNA-7 in
922

923 **Figure 3. (See previous page). MiR-7 controls intestinal epithelial growth ex vivo.** (A) Experimental design for testing the
924 effect of miR-7 suppression in enteroid culture established from C57BL/6 WT mouse jejunum. (B) RT-qPCR data showing
925 effective suppression of miR-7 expression by LNA-7 treatments in mouse enteroids compared with mock (no treatment) and
926 LNA-scr control (n = 5–6 wells per condition pooled from 2 independent experiments). (C) Small RNA-seq followed by dif-
927 ferential expression analysis showing highly robust and specific suppression of all the miR-7 family members in the enteroids
928 treated with LNA-7 compared with LNA-scr (LNA-7, n = 6; LNA-scr, n = 5). (D) Representative bright field images of enteroids
929 treated with mock, LNA-scr, and LNA-7. (E) Bar graph depicting average number of buds per enteroid in the indicated
930 treatment groups. Data were pooled from 3 independent experiments (mock, n = 174 enteroids; LNA-scr, n = 214 enteroids;
931 LNA-7, n = 163 enteroids). (F) The left panel shows RT-qPCR data showing effective suppression of miR-7 by LNA-7 (n = 5
932 wells/condition) in porcine enteroids. The right panel shows bar graph depicting average number of buds per porcine enteroid
933 in the indicated treatment groups. Enteroids were pooled from 5 independent experiments (mock, n = 83; LNA-7, n = 86
934 enteroids). (G) Representative images of mouse enteroids showing whole-mount staining signal for EdU (green; top) and PH3
935 (red; bottom). (H) Bar graph depicting average number of PH3+ cells per enteroid. All of the enteroids across multiple wells
936 were examined (mock, n = 100 enteroids; LNA-scr, n = 83 enteroids; LNA-7, n = 106 enteroids). (I) RT-qPCR data showing
937 effective increase in miR-7 levels in mouse enteroids treated with mimics of miR-7 (mimics-miR-7) compared with mock (no
938 treatment) and mimics-scramble (mimics-scr) (n = 3 wells per group). (J) Representative brightfield images of wild-type mouse
939 enteroids (top) and whole-mount staining signal for PH3 (red; bottom) in the indicated treatments. (K) Quantification of the
940 average number of buds per enteroid in the indicated treatments. Enteroids per treatment group were pooled from multiple
941 wells for quantification (mock, n = 175; mimics-scr, n = 168; mimics-miR-7, n = 116). (L) Quantification of the average number
942 of PH3+ cells per enteroid in the indicated treatments. All of the enteroids across multiple wells were examined (mock, n = 123
943 enteroids; mimics-scr, n = 190 enteroids; mimics-miR-7, n = 165 enteroids). * *P* < .05, ** *P* < .01 and *** *P* < .001 by 2-tailed
944 Student *t* test. RQV, relative quantitative value.

Table 2. Small RNA-seq Analysis Showing Differentially Expressed miRNAs (Adjusted $P < .05$) in Mouse Enteroids Treated With LNA-7 ($n = 6$) Relative to LNA-scr ($n = 5$)

miRNA	log2FoldChange	Adjusted P
mmu-mir-7a-1-5p	-7.109435038	4.64E-43
mmu-mir-7a-2-5p	-7.103216777	5.31E-43
mmu-let-7f-1-5p	-0.854266518	8.57E-14
mmu-let-7f-2-5p	-0.862650621	1.58E-13
mmu-mir-215-5p	-1.460451901	3.96E-10
mmu-mir-148a-3p	0.495197848	5.41E-05
mmu-mir-215-5p_+_1	-1.050094118	1.02E-04
mmu-mir-192-5p_+_2	0.309404578	2.82E-04
mmu-mir-98-5p	-0.509809453	4.18E-04
mmu-let-7i-5p	-0.402567428	.001535664
mmu-mir-30d-5p	0.317770352	.004397959
mmu-mir-26a-2-5p	0.149129242	.004685784
mmu-mir-26a-1-5p	0.149100629	.004685784
mmu-mir-203-3p_+_1	0.592648674	.009726977
mmu-mir-30e-3p	0.276607739	.010577384
mmu-mir-192-5p_+_1	0.204704048	.010887894
mmu-mir-192-5p	0.206058351	.01488005
mmu-let-7g-5p	-0.48204363	.035030773

miRNA, microRNA; RNA-seq, RNA sequencing.

the context of direct *Egfr* suppression. We first demonstrated in mouse enteroids that treatment with an oligonucleotide inhibitor of *Egfr* (Gapmer *Egfr*) downregulates *Egfr* messenger RNA levels by $\sim 60\%$ (Figure 6A) and significantly reduces enteroid budding as expected (Figure 6B and 6C). Then we showed that treatment of enteroids with Gapmer *Egfr* significantly blunts the proliferative phenotype observed with LNA-7 alone or with Gapmer Control, as determined by budding (Figure 6D and 6E) and EdU staining (Figure 6E). Also, we demonstrated that *Egfr* suppression greatly blunts the hyperbudding phenotype in LNA-7-treated enteroids compared with LNA-scr-treated enteroids (Figure 6F).

A previous study established that *Egfr* signaling can suppress EEC differentiation.²⁸ Given the finding that miR-7 function is dependent in part on *Egfr* signaling, we hypothesized that loss of miR-7 may shift the balance of secretory progenitor cells toward proliferation and away from EEC maturation. Indeed, in our single-cell RNA-seq data from mouse enteroids, we found that LNA-7 treatment increases the proportion of Prox1+ cells (proliferative EEC progenitors) and decreases the proportion of Chga+ cells (mix of EEC progenitors primed to differentiation and mature EECs) in the progenitor population (Figure 6G and 6H). To validate this observation, we showed that treatment of enteroids with LNA-7 leads to a significant increase in Prox1-EGFP+ cells/enteroid (Figure 6I) and a significant decrease in Chga+ cells/enteroid (Figure 6J). Taken together, these data strongly suggest that EEC progenitor enriched miR-7, in part through *Xiap* and *Egfr*, controls

enteroid budding (proxy for crypt division) and may also be involved in the regulation of EEC abundance (Figure 6K).

Discussion

Although miRNAs are well appreciated as regulators of cell division, growth, and differentiation in many organ systems, their contributions in the intestinal epithelium remain largely unknown. Recently, several studies have reported that EEC progenitors represent a plastic cell population that can either drive the formation of mature EECs or exhibit stem cell-like proliferative capacity.^{3,4} Here, we have (1) identified miR-7 as a highly enriched miRNA across the entire EEC lineage trajectory, using 8 different reporter mice, FACS, and small RNA-seq; (2) defined miR-7 as the most enriched miRNA in EEC progenitors relative to Lgr5+ stem cells; (3) demonstrated that miR-7 in the EEC progenitor population is dramatically suppressed under physiological conditions of increased crypt division; (4) showed that miR-7 controls enteroid budding and EEC progenitor cell behavior; and (5) showed that miR-7 function depends at least in part on intact *Xiap* and downstream *Egfr* signaling. To our knowledge, this is the first report of a miRNA enriched along the EEC lineage trajectory that exerts substantive control of enteroid growth and likely EEC abundance. Although previously miR-7 has been reported to have roles in specific cancer contexts,^{17,29,30} our study is the first to our knowledge to demonstrate that miR-7 regulates intestinal growth under normal physiological conditions. It is noteworthy that modest but significant changes in miRNA expression, similar to what we show for miR-7 in this study, have been linked functionally to important phenotypes in numerous prior studies.³¹⁻³³


Although our data suggest that miR-7 has important roles in EEC progenitor cells, we also cannot rule out functions in other stem or progenitor cell types. Also, though we have demonstrated that manipulating miR-7 expression regulates intestinal epithelial proliferative capacity, whether miR-7 controls the abundance of specific subtypes of mature EECs requires future detailed investigation. In addition, we have observed downregulation of miR-7 only in EEC progenitors but not in mature EECs upon HFD (Figure 2), motivating the question of what upstream mechanisms regulate miR-7 in this cell-type specific manner. A study in *Drosophila* showed that *Ato*, the mammalian ortholog of which is *Atoh1* (a known EEC lineage driver in mouse), is upstream of miR-7 during development.³⁴ Whether *Atoh1* regulates miR-7 in the mammalian intestinal epithelium and whether *Atoh1* is responsible for the alteration of miR-7 expression upon HFD remain to be determined in the future.

Though mature EECs constitute only $\sim 1\%$ of cells in the intestinal epithelium, they are critical for orchestrating proper responses to nutritional and microbial input to maintain energy homeostasis and immune function.³⁵⁻³⁷ They are known to secrete many different kinds of hormones that function through endocrine and paracrine signaling, and they are thought to be major contributors to the immediate, weight loss-independent positive metabolic

1061 effects of bariatric surgery.³⁸ Also, recent studies have
1062 implicated EECs in the gut-brain axis and the immune-
1063 endocrine axis through direct connection to enteric ner-
1064 vous system and surrounding immune cells, respectively.³⁹
1065 While changes in EEC abundance or function have been
1066 linked to a wide array of diseases including diabetes, in-
1067 flammatory bowel disease, and psychiatric or neurologic
1068 disorders,^{40,41} the key regulators of the EEC lineage remain
1069 incompletely characterized due in part to the rareness, high
1070 molecular heterogeneity, and plasticity of this cell popula-
1071 tion. In the present study, we uncovered the functional role
1072 of EEC lineage-enriched miR-7 particularly in regulating
1073 intestinal epithelial growth and also provided observations
1074 suggesting its role in regulating EEC abundance. The

potential role of miR-7 in regulating EEC maturation and
function warrants future studies.

In vivo loss-of-function studies of miR-7 are made
extremely challenging by the fact that there are 3 different
miR-7 paralogs in mice: miR-7a-1, miR-7a-2, and miR-7b.
We believe that the current study provides strong motiva-
tion to invest in the generation of an EEC progenitor
cell-specific miR-7 triple-knockout mouse colony. These
mice will be useful for future in vivo investigation of the role
of miR-7 in intestinal epithelial proliferation and renewal
under baseline conditions and in response to different
perturbations that affect crypt behavior, including HFD,
pathogenic gastrointestinal infection, irradiation, or even
bariatric surgery. Finally, we note that this study identifies
several other miRNAs in addition to miR-7 that are enriched
in the EEC lineage trajectory and altered under conditions of
increased crypt budding. It will also be of great interest to
investigate the role of these miRNAs too, in isolation and in
conjunction with miR-7, in controlling the biology and
pathophysiology of the crypt in the intestinal epithelium.



Materials and Methods

Animal Models and Diet Study

The following transgenic reporter mice were utilized: female and male Sox9-EGFP,⁴² female Lgr5-EGFP,²⁴ female Prox1-EGFP,⁴³ female Pyy-EGFP mice,⁴⁴ male and female Defa6-CreERT;Rosa26-tdTomato mice,⁴⁵ and male and female Hopx-CreERT;Rosa26-tdTomato mice (JAX strains 017606, 007914; Jackson Laboratory, Bar Harbor, ME). For the diet study, 8- to 10-week-old C57BL/6 wild-type mice and, either 8- to 10-week-old Lgr5-EGFP female mice (for histomorphometry and metabolic phenotyping) or adult 8- to 10-week-old Sox9-EGFP female mice (for cell sorting and RNA-seq), were fed ad libitum with either an LFD (14% kcal from fat; Prolab RMH3000) or an HFD (45% kcal from fat; Research Diets D12451) for 16 weeks. Body weight, body composition and blood parameters were measured to confirm obesity phenotype. To mark cells in S-phase, EdU

Figure 4. MiR-7 controls intestinal epithelial proliferation in *Drosophila* midgut in vivo.


(A) Mature miR-7 sequence across different species, including human, pig, mouse, and fruit fly. The seed sequence is denoted in red. (B) Heatmap results of small RNA-seq analysis of *Drosophila melanogaster* midgut showing miRNAs that are significantly ($P < .05$) upregulated or downregulated upon exposure to the proliferative *Ecc15* pathogen ($n = 3$) relative to unchallenged (UC) condition ($n = 3$). Only showing those miRNAs with average reads per million mapped to miRNAs >100 in either *Ecc15* challenge or UC. (C) Downregulation of miR-7 in the *D. melanogaster* midgut at 4 hours (minimal proliferative response, $n = 3$) and 12 hours (peak proliferative response, $n = 3$) after *Ecc15* challenge compared with the UC control group. (D) Immunofluorescent staining of DAPI (blue) and Esg (green) in *D. melanogaster* midgut with mock (left), *Ecc15* alone (middle), and *Ecc15* with miR-7 overexpression driven by the Esg promoter (overexpressed miR-7 [miR-7 OE]) (right). (E) Bar graph showing counts of PH3+ replicating cells in the *D. melanogaster* midgut of each. * $P < .05$, ** $P < .01$, and *** $P < .001$ by 2-tailed Student *t* test.

1179 was administered by intraperitoneal injection (100 μ g/25 g
1180 body weight) 90 minutes before euthanizing. The harvested
1181 small intestine was divided into 3 equal segments. The
1182 middle region was considered the jejunum. All animal pro-
1183 cedures were performed with the approval and authoriza-
1184 tion of the Institutional Animal Care and Use Committee at
1185 each participating institution.

1187 **Flow Cytometry**

1188 Six distinct reporter mouse strains that facilitate the
1189 sorting of a variety of different intestinal epithelial cell types

were used to isolate aISCs (Lgr5-EGFP), EEC progenitors
(Sox9-EGFP and Prox1-EGFP), mature EECs (Sox9-EGFP and
Pyy-EGFP), Paneth cells (Defa6-CreERT2;Rosa26-
tdTomato), and rISCs (Hopx-CreERT2;Rosa26-tdTomato).
Mouse intestinal epithelial cells from the jejunum were
dissociated and prepared for fluorescence-activated cell
sorting (FACS) as described previously.²⁰ CD31-APC (Bio-
Legend, San Diego, CA), CD45-APC (BioLegend), and
Annexin-V-APC (Life Technologies, Carlsbad, CA), and Sytox-
Blue (Life Technologies) staining were used to exclude
endothelial cells, immune cells, and apoptotic cells,



1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237

1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296

1297 respectively. The gating parameters of FACS sorting were
1298 described previously.²⁰ The Lgr5, Sox9, and Defa6 sorts
1299 were performed using a Mo-Flo XDP cell sorter (Thermo
1300 Fisher Scientific, Fullerton, CA) at the University of North
1301 Carolina Flow Cytometry Core Facility. The Prox1 sorts were
1302 performed using BD FACS Aria Fusion Fluorescence Acti-
1303 vated Cell Sorter (BD Biosciences, San Jose, CA) at Cornell
1304 University Flow Cytometry Core Facility at the Biotech-
1305 nology Resource Center. The Pyy sorts were performed
1306 using BD FACS Aria II Cell Sorter (BD Biosciences) at Kings
1307 BRC flow cytometry Core facility. Sorting of Hopx+ cells was
1308 conducted at North Carolina State University, College of
1309 Veterinary Medicine using a Mo-Flo XDP cell sorter (Beck-
1310 man Coulter). The cells were sorted directly into cold Dul-
1311 becco's modified Eagle medium or lysis buffer.

1312 Tuft cells were sorted by use of the cell surface marker
1313 ^{Q5}SiglecF. Mouse jejunal cells were prepared as described
1314 previously.⁴⁶ Aqua Live Dead fixable viability stain Live dye
1315 (Thermo Fisher Scientific, Waltham, MA) and anti-mouse
1316 EpCam-APC (clone G8.8; Thermo Fisher Scientific) staining
1317 was used to include viable, epithelial cells, respectively,
1318 while anti-mouse CD45 BV605 staining (clone 30-F11; BD
1319 Biosciences) was used to exclude immune cells. Anti-mouse
1320 SiglecF-PE antibody (clone E50-2440; Thermo Fisher Sci-
1321 entific) was employed to enrich for tuft cells. Sorting for tuft
1322 cells was performed using BD FACS Aria Fusion II Fluores-
1323 cence Activated Cell Sorter (BD Biosciences) at Cornell
1324 University Flow Cytometry Core Facility, Biotechnology
1325 Resource Center. Cells were sorted directly into cold lysis
1326 buffer (Norgen Biotek, Thorold, Canada).

1327 Side population sorting was used to separate the sub-
1328 fraction of slowly cycling from active cycling intestinal stem
1329 cells, as described previously.¹⁸ Mouse intestinal epithelial
1330 cells from the jejunum of female C57BL/6 mice were pre-
1331 pared and sorted into either upper side population (con-
1332 sisting of actively cycling stem cells) or lower side
1333 population (consisting of slowly cycling stem cells) by the
1334

1356 previously described gating methods.¹⁸ The side population
1357 sorting⁴⁶ was performed using a Mo-Flo XDP cell sorter
1358 (Beckman Coulter) at the University of North Carolina Flow
1359 Cytometry Core Facility. Cells were sorted directly into cold
1360 lysis buffer (Norgen).
1361

1362 *Histological Analysis*

1363 Mouse jejunal tissue was fixed in 4% (v/v) neutral-
1364 buffered paraformaldehyde, embedded in paraffin, and cut
1365 into 5- μ m sections for various staining experiments. He-
1366 matoxylin and eosin staining was performed for morpho-
1367 metric analyses (villi height and crypt density). Crypt
1368 density was calculated by dividing the number of well-
1369 oriented crypts per millimeter of submucosal
1370 circumference. EdU staining was performed to visualize
1371 cells in S-phase using the Click-iT EdU AlexaFluor 594 Kit
1372 (Invitrogen, Carlsbad, CA). Immunofluorescent staining of α -
1373 chromogranin (Chga) was performed for assessing mature
1374 EEC number. Briefly, sections were incubated with primary
1375 antibody (rabbit Chga, 1:100 dilution in immunofluores-
1376 cence buffer; ab15160; Abcam, Cambridge, United Kingdom)
1377 overnight at 4°C followed by Alexa Fluor 594 (Abcam)
1378 secondary antibody incubation for 2 hours at room tem-
1379 perature. DAPI (1:1000) was used to visualize nuclei. Im-
1380 ages were captured using ZEISS Axiovert 200M inverted ^{Q6}
1381 microscope. The numbers of Chga+ cells per villus were
1382 normalized by average villus height (millimeters) in each of
1383 the diet groups. For the villus height measurements, 1 data
1384 point from LFD group and 1 data point from HFD were
1385 removed as outliers after applying the criterion of value
1386 beyond average \pm 1.5*standard deviation.
1387

1388 *RNA Extraction and Real-Time qPCR*

1389 Total RNA was isolated using the Total or Single-cell
1390 RNA Purification kit (Norgen Biotek). High Capacity RNA
1391 to cDNA kit (Life Technologies, Grand Island, NY) was used
1392 for reverse transcription of RNA. TaqMan microRNA
1393












1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414

Figure 5. (See previous page). MiR-7 control of enteroid budding is dependent on intact *Xiap*. (A) t-SNE plot of single-cell RNA-seq profiles reveals 3 major cell populations: enterocytes, Paneth cells, and progenitor or stem cells, from mouse enteroids treated with LNA-7 or LNA-scr (enterocytes, n = 107 cells; Paneth cells, n = 54; progenitor/stem, n = 71). The clusters were assigned based on overlap with marker genes for every major intestinal epithelial cell type defined in Haber et al., 2017. (B) t-SNE plot of single-cell RNA-seq data showing expression level for *Apoa1* (top, enterocyte marker) and *Cenpa* (bottom, progenitor cell marker). (C) Heatmap displaying average expression of cell type-specific markers for cells in each cluster from LNA-scr- or LNA-7-treated mouse enteroids. Expression is scaled by row. (D) Average *Xiap* expression across all cells from LNA-scr- or LNA-7-treated mouse enteroids (Wilcox). (E) Percentage of *Xiap*+ cells present in the single-cell RNA-seq data from mouse enteroids treated with LNA-scr or LNA-7. (F) Percentage of *Xiap*+ progenitor/stem cells present in the single-cell RNA-seq data from mouse enteroids treated with LNA-scr or LNA-7. (G) RT-qPCR data showing suppression of miR-7 (left panel) and the upregulation of *XIAP* (right panel) in human intestinal organoids treated with LNA-7 compared with LNA-scr (n = 3 wells per condition). (H) Representative images and quantification of whole-mount staining signal for *Xiap* (red) and Hoechst (blue) in mouse enteroids with the indicated treatment groups (mock, n = 99 enteroids; GDC0152, n = 69 enteroids). (I) Representative bright field images and quantification of average number of buds per enteroid with mock treatment (no treatment) or *Xiap* inhibitor treatment (GDC0152) (mock, n = 274 enteroids; GDC0152, n = 120 enteroids). (J) Representative images and quantification of whole-mount staining signal for *Xiap* (red) and Hoechst (blue) in the indicated treatment groups. Data from enteroids across multiple wells were examined (LNA-scr, n = 112 enteroids; LNA-7, n = 41 enteroids; GDC0152+LNA-scr, n = 18 enteroids; GDC0152+LNA-7 = 32 enteroids). (K) Representative bright field images and quantification of the average number of buds per enteroid after LNA-scr treatment or LNA-7 treatment with and without GDC0152 (LNA-scr, n = 192 enteroids; LNA-7, n = 118 enteroids; GDC0152+LNA-scr, n = 96 enteroids; GDC0152+LNA-7, n = 44 enteroids). (L) Representative images and quantification of whole-mount staining signal for PH3 (red) and Hoechst (blue) in the indicated treatment groups. Data from enteroids across multiple wells were examined (LNA-scr, n = 92 enteroids; LNA-7, n = 45 enteroids; GDC0152+LNA-scr, n = 58 enteroids; GDC0152+LNA-7 = 62 enteroids). * $P < .05$, ** $P < .01$ and *** $P < .001$ by 2-tailed Student *t* test. RQV, relative quantitative value.

1415 Reverse Transcription kit (Life Technologies) was used for
 1416 reverse transcription of miRNA. Both miRNA and gene
 1417 expression qPCR were performed using TaqMan assays (Life
 1418 Technologies) with either TaqMan Universal PCR Master
 1419 Mix (miRNA qPCR) or TaqMan Gene Expression Master Mix
 1420 (messenger RNA qPCR) per the manufacturer's protocol, on
 1421 a Bio-Rad CFX96 Touch Real Time PCR Detection System
 1422 (Bio-Rad Laboratories, Richmond, CA). Reactions were per-
 1423 formed in triplicate using either U6 (miRNA qPCR), Rps9
 1424 (mouse messenger RNA qPCR) or RNU48 (human
 1425 messenger RNA qPCR) as the normalizer.

Small RNA Library Preparation and Sequencing

1474 The small RNA-seq of cells from the various cell sorts
 1475 and *D. melanogaster* midgut was conducted at Genome
 1476 Sequencing Facility of Greehey Children's Cancer Research
 1477 Institute at University of Texas Health Science Center at San
 1478 Antonio. Libraries were prepared using the TriLink Clean-
 1479 Tag Small RNA Ligation kit (TriLink Biotechnologies, San
 1480 Diego, CA). Seven to 8 libraries were sequenced per lane,
 1481 with single-end 50x on the HiSeq2500 platform. Raw
 1482 sequencing data and miRNA quantification tables can be
 1483 accessed through GEO record GSE118814.
 1484
 1485
 1486
 1487
 1488
 1489
 1490
 1491
 1492
 1493
 1494
 1495
 1496
 1497
 1498
 1499
 1500
 1501
 1502
 1503
 1504
 1505
 1506
 1507
 1508
 1509
 1510
 1511
 1512
 1513
 1514
 1515
 1516
 1517
 1518
 1519
 1520
 1521
 1522
 1523
 1524
 1525
 1526
 1527
 1528
 1529
 1530
 1531
 1532



1470
 1471
 1472
 1473
 web 4C/FPO

1533 RNA Library Preparation and Sequencing

1534 RNA-seq libraries from the Sox9 sorts of LFD-fed and
1535 HFD-fed C57BL/6J mice were prepared using the Clontech
1536 SMARTer Ultra Low Input library preparation kit combined
1537 with Nextera XT DNA sample preparation kit (Illumina, San
1538 Diego, CA) and sequenced with single-end 100 bp on a
1539 HiSeq2000 platform at the UNC High Throughput
1540 Sequencing Core Facility, as previously described.⁴⁷ Raw
1541 sequencing data as well as normalized counts are available
1542 through GEO accession GSE118814.

1543 Single Cell Suspension Preparation, RNA Library 1544 Preparation, and Sequencing

1545 Enteroids treated with either LNA-7 or LNA-scr were
1546 harvested at day 5. Briefly, media was removed from
1547 enteroid cultures and the enteroids were washed twice with
1548 ice-cold phosphate-buffered saline (PBS). Enteroids were
1549 collected in cold PBS, spun down at 300 *g* for 5 minutes, and
1550 resuspended as a pellet in 10 mL of ice-cold D-PBS with
1551 0.04% (w/v) bovine serum albumin (BSA). Centrifugation at
1552 1000 *g* at 4°C was carried out for 5 minutes. Supernatant
1553 was removed and the pellet was resuspended in 10 mL of
1554 room temperature Hank's Balanced Salt Solution with 0.3-
1555 U/mL dispase. Incubation in a water bath was performed
1556 at 37°C for 12–16 minutes. The tubes were gently shaken
1557 every 2 minutes. An aliquot was examined under the mi-
1558 croscope to determine whether >50% of the cells were
1559 single cells. Dispase activity was stopped by adding fetal
1560 bovine serum to 10% of the total volume of samples and
1561 DNaseI to a final concentration of 50 µg/mL (50 µL). Sam-
1562 ples were filtered with 40-µm strainer and centrifuged at
1563 500 *g* at 4°C for 5 minutes. The supernatant was removed
1564 and the pellet was resuspended in 10 mL of ice-cold Hank's
1565 Balanced Salt Solution, and the samples were filtered again
1566 with 40 µm strainer and centrifuged at 500 *g* at 4°C for 5
1567 minutes. The supernatant was removed and the pellet was
1568 resuspended in 100 µL of ice-cold D-PBS with 0.04% (w/v)
1569 BSA. The samples were gently mixed several times with
1570 wide-bore pipet tip (1000-µL pipet tip), and then checked
1571 under the microscope for any clumping. If clumps were
1572 present, the filtration, centrifugation, and resuspension
1573
1574
1575

steps were repeated. Finally, cell viability and cell number
were determined using Trypan blue and Bio-Rad cell
counter to proceed with single cell library preparation and
sequencing. For single cell sequencing, we used the 10X
Genomics Chromium instrument at the Cornell Genomics
Facility.

Bioinformatics Analysis

Bulk Small RNA and RNA-Seq Analysis. Small RNA-seq
reads were aligned to the mouse genome (mm9) and
quantified using miRquant 2.0 as previously described,⁴⁸
with the exception that raw miRNA counts were normal-
ized using DESeq2,⁴⁹ to determine significance. Fruit fly
sequences were depleted for a dominant rRNA species
before alignment to the full genome (dm3). miRNA anno-
tation was performed using miRbase (r18 for mouse and
r21 for fruit fly). RNA-seq reads were mapped to mouse
genome release mm10 using STAR (v2.5.3a)⁵⁰ and tran-
script quantification was performed using Salmon
(v0.6.0).⁵¹ Differential gene expression analysis was
accomplished using DESeq2.⁴⁹

Single Cell RNA-Seq Analysis. Single-cell RNA-seq reads
for 107 LNA-7 and 158 LNA-scr cells were aligned to the
mouse genome (mm10) and quantified using 10X Genomics
Cell Ranger count. Cells with low gene complexity (<200
genes/cell) or with a strong mitochondrial signature (>25%
mitochondrial genes) were filtered, resulting in 92 LNA-7
and 140 LNA-scr cells. Cluster identification, differential
expression analysis, and t-SNE plot generation were per-
formed with Seurat_3.0.1.

Other. MiRNA binding site enrichment among differentially
expressed genes was determined using miRhub.²² Tran-
scription factor enrichment was determined by inputting
the top 20 significant upregulated genes into Enrichr^{52,53}
and using the ENCODE and ChEA Consensus TFs from the
ChIP-X dataset.

Enteroid Culture

Mouse Enteroids. Jejunal crypts were isolated from 3- to
5-month-old female C57BL/6 mice as previously
described.⁴⁷ The isolated crypts (day 0) were grown into

Figure 6. (See previous page). MiR-7 control of enteroid budding depends on Egfr signaling. (A) RT-qPCR data showing
Egfr expression in mouse enteroids treated with control Gapmer inhibitor (n = 2) or *Egfr* Gapmer inhibitor (n = 2) on day 5. (B)
Quantification of the average number of buds per enteroid treated with mock (no treatment), Gapmer Control, or Gapmer *Egfr*
(Mock, n = 194 enteroids; Gapmer Control, n = 88 enteroids; Gapmer *Egfr*, n = 149 enteroids). (C) Representative bright field
images of mouse enteroids with treatment of Gapmer Control and Gapmer *Egfr*. (D) Quantification of the average number of
buds per mouse enteroid in the indicated treatments (LNA-7, n = 55 enteroids; LNA-7 + Gapmer control, n = 53 enteroids;
LNA-7 + *Egfr* Gapmer, n = 27 enteroids). (E) Representative images showing whole-mount staining of EdU (top; red), Hoechst
(top; blue), and bright field (bottom) in mouse enteroids with the indicated treatments. (F) Quantification of the average number
of buds per mouse enteroid in the indicated treatments (LNA-scr, n = 165 enteroids; LNA-7, n = 182 enteroids; LNA-scr +
Gapmer *Egfr*, n = 91 enteroids; LNA-7 + Gapmer *Egfr*, n = 148 enteroids). (G) Percentage of *Prox1*+ progenitor or stem cells
present in the single-cell RNA-seq data from mouse enteroids treated with LNA-scr or LNA-7. (H) Percentage of *Chga*+
progenitor/stem cells present in the single-cell RNA-seq data from mouse enteroids treated with LNA-scr or LNA-7. (I)
Representative images of *Prox1*+ cells (green) and quantification of *Prox1*+ cells per mouse enteroid established from *Prox1*-
EGFP reporter mice in the indicated treatments (mock, n = 30 enteroids; LNA-scr, n = 46 enteroids; LNA-7, n = 26 enteroids).
(J) Representative images of *Chga*+ cells (red) and quantification of *Chga*+ cells per mouse enteroid in the indicated treat-
ments (mock, n = 96 enteroids; LNA-scr, n = 92 enteroids; LNA-7, n = 113 enteroids pooled from 2 independent experiments).
(K) The proposed partial working model of miR-7 control of intestinal epithelial proliferation. * *P* < .05, ** *P* < .01 and *** *P* <
.001 by 2-tailed Student *t* test.

1651 Reduced Growth Factor Matrigel (cat. 356231; Corning,
1652 Corning, NY). Advanced DMEM/F12 (cat. 12634-028; Gibco,
1653 Gaithersburg, MD) supplemented with GlutaMAX (cat.
1654 35050-061; Gibco), Pen/Strep (cat. 15140; Gibco), HEPES
1655 (cat. 15630-080; Gibco), N2 supplement (cat. 17502-048;
1656 Gibco), 50-ng/mL EGF (cat. 2028-EG; R&D Systems, Min-
1657 neapolis, MN), 100- μ g/mL Noggin (cat. 250-38; PeproTech,
1658 Rocky Hill, NJ), 250-ng/ μ L murine R-spondin (cat. 3474-RS-
1659 050, R&D Systems), and 10-mM Y27632 (cat. ALX270-333-
1660 M025; Enzo Life Sciences, East Farmingdale, NY) was added.
1661 For miRNA loss-of-function studies, miRCURY LNA Power
1662 Inhibitor against mouse miR-7 (mmu-miR-7a-5p) (cat.
1663 YI04100818-DDA; Qiagen, Hilden, Germany) or Power
1664 Negative Control A (cat. YI00199006-DDA; Qiagen) was
1665 added at 500 nM on day 0 and supplemented at 250 nM on
1666 day 3. For miRNA gain-of-function studies, miRCURY LNA
1667 mimic of miR-7 (cat. YM00472714-AGA; Qiagen) or Nega-
1668 tive Control (cat. YM00479902-AGA; Qiagen) was added at
1669 500 nM on day 0 and supplemented at 250 nM on day 3.
1670 Enteroids at day 5 were harvested for RNA isolation or fixed
1671 in 2% (v/v) paraformaldehyde for whole-mount staining.

1672 For studies knocking down *Egfr*, LNA-7-treated enter-
1673 oids were treated with a custom LNA GapmeR against *Egfr*
1674 (*Egfr* GapmeR-A Design ID: LG00204888-DDA, *Egfr*
1675 GapmeR-B Design ID: LG00204889-DDA, *Egfr* GapmeR-C
1676 Design ID: LG00204890-DDA; Qiagen) or Negative Control
1677 A GapmeR (Design ID: LG00000001-DDA; Qiagen) at 500 nM
1678 at day 0 and supplemented at 250 nM at day 3. Enteroids at
1679 day 5 were harvested for RNA isolation or fixed in 2% (v/v)
1680 paraformaldehyde for whole-mount staining. For EdU
1681 staining assays, enteroids were treated with 10-mM EdU 6
1682 hours before the harvest time point follow by the manu-
1683 facturer's protocol of Click-iT EdU Alexa Fluor 488 Flow
1684 Cytometry Assay Kit (C10425; Thermo Fisher Scientific).

1685 For studies inhibiting *Xiap* function, enteroids were
1686 treated with GDC0152 (Cat. # S7010; SelleckChem, Houston,
1687 TX), which inhibits the activity of inhibitors of apoptosis
1688 proteins (IAPs) including X chromosome-linked IAP (XIAP)
1689 and IAPs 1 and 2 and promote apoptosis. The enteroid
1690 culture was treated alone with GDC0152 at 0.25 μ M or co-
1691 treated with LNA at day 0. At day 5, enteroids were fixed in
1692 2% (v/v) paraformaldehyde for brightfield imaging and
1693 whole-mount staining.

1694 **Porcine Enteroids.** Jejunal crypts were isolated from 6- to
1695 10-week-old, mixed gender, wild type Yorkshire cross pigs
1696 as previously described.⁵⁴ The isolated crypts (day 0) were
1697 cultured in Reduced Growth Factor Matrigel (cat. 356231;
1698 Corning) and maintained in DMEM/F12 medium (cat.
1699 12634-010; Life Technologies) supplemented with 50-ng/
1700 mL EGF (cat. 236-EG; R&D Systems), 100-ng/mL Noggin
1701 (cat. 120-10C; PeproTech), 1 μ g/mL R-Spondin (cat.
1702 4645RS/CF, R&D Systems), 500-nM A83-01 (cat. 2939;
1703 Tocris Bioscience, Bristol, United Kingdom), 10- μ M
1704 SB202190 (cat. S7067; Sigma-Aldrich, St. Louis, MO), 1-mM
1705 Nicotinamide (cat. N0636, Sigma), 10-nM Gastrin (cat.
1706 G9145; Sigma), 10- μ M Y-27632 (cat. Y0503; Sigma), and
1707 100-ng/mL Wnt3a (cat. 5036-WN/CF; R&D Systems). For
1708 miRNA studies, miRCURY LNA Power Inhibitor against miR-
1709 7 (mmu-miR-7a-5p miRCURY LNA miRNA Power Inhibitor,

cat. YI04100818-DDA; Qiagen) or Power Negative Control A
1710 (cat. YI00199006-DDA; Qiagen) were added on day 0 and
1711 enteroids were harvested on day 3.

1712 **Human Enteroids.** Human duodenal enteroids were pre-
1713 viously established from tissue collected from deceased
1714 donors through the Gift of Life, Michigan (University of
1715 Michigan IRB REP00000105; not regulated designation).
1716 For this study, specimen Duo-87 from a 21-year-old male
1717 were used (Translational Tissue Modeling Laboratory).
1718 Enteroids were cultured in medium containing 25% (v/v) L-
1719 WRN conditioned medium. The complete medium contained
1720 Advanced DMEM/F-12 (cat. 12634028; Gibco), 2-mM Glu-
1721 taMax (cat. 35050-061; Gibco), 10-mM HEPES (cat.
1722 15630080; Gibco), N-2 (cat. 17502048; Gibco), B-27 sup-
1723 plement minus vitamin A (cat. 12587010; Gibco), 50 units/
1724 mL of penicillin, 0.05-mg/mL streptomycin (cat. 15070063;
1725 Gibco), 50- μ g/mL Primocin (##ant-pm-1; InvivoGen, San
1726 Diego, CA), 1-mM N-Acetyl-L-cysteine (A9165; Sigma-
1727 Aldrich), 50-ng EGF/mL (236-EG; R&D Systems), 10- μ M
1728 SB202190 (S7067; Sigma-Aldrich), 500-nM A83-01 (#2939;
1729 R&D Tocris), and 10- μ M Y27632 (125410; Tocris Biosci-
1730 ence). Cultures were grown in Matrigel (diluted to 8 mg/mL
1731 with growth media; #354234; Corning). Cultures were
1732 passed by trituring and dissociating the Matrigel in cold
1733 DPBS, centrifuging at 300 *g*, and plating the first day with
1734 2.5- μ M CHIR99021 (4423; Tocris Bioscience). For miRNA
1735 studies, miRCURY LNA Power Inhibitor against miR-7
1736 (mmu-miR-7a-5p miRCURY LNA miRNA Power Inhibitor;
1737 cat YI04100818-DDA; Qiagen) or Power Negative Control A
1738 (cat. YI00199006-DDA; Qiagen) were added on day 0 and
1739 enteroids were harvested on day 5.

1740 Whole-Mount Enteroids Immunostaining and 1741 Imaging

1742 The fixed mouse enteroids were permeabilized with 0.5%
1743 (v/v) Triton X-100/PBS, washed by PBS containing 0.1% (w/
1744 v) BSA/0.02% (v/v) Triton-X/0.05% (v/v) Tween 20 and
1745 blocked with 10% (v/v) normal goat serum. Primary anti-
1746 bodies were used to stain Chga (rabbit anti-Chga, 1:100;
1747 ab15160; Abcam) and PH3 (rabbit anti-Phospho-Histone H3
1748 (Ser10), 1:100, 9701S; Cell Signaling) and *Xiap* (1:100; rabbit,
1749 NBP2-20918; Novus Biologicals, Centennial, CO). The staining
1750 was visualized by fluorescence microscopy with fluorescent-
1751 conjugated secondary antibodies (goat anti-rabbit; Alexa
1752 Fluor 488, 1:400; Cat. #A-11034; Thermo Fisher Scientific).
1753 Nuclei were counterstained with Hoechst 33258 dye
1754 (1:1000). For EdU staining assays, enteroids were treated
1755 with 10-mM EdU 6 hours before the harvest time point
1756 follow by the manufacturer's protocol of Click-iT Plus EdU
1757 Alexa Fluor 488/594 imaging Kit (C10637, C10639; Thermo
1758 Fisher Scientific). The immunofluorescent staining was visu-
1759 alized by ZEISS Axiovert 200M inverted microscope. The z-
1760 stack bright field images were taken by ZEISS Axiovert 200M
1761 inverted microscope for bud count analysis.

1762 *Ecc15* Infection in *D. melanogaster*

1763 Wide type line Canton-S (BDSC: 64349) was maintained
1764 at room temperature ($\sim 23^{\circ}\text{C}$) on standard fly medium (50-
1765 1766 1767 1768

1769 g baker yeast, 30-g cornmeal, 20-g sucrose, 15-g agar, 5-mL
1770 99% [v/v] propionic acid mix, 0.5-mL 85% [v/v] phosphoric
1771 acid, 26.5-mL methyl paraben in ethanol per 1 L) in a 12-
1772 hour light/dark cycle. Oral infection of pathogen *Erwinia*
1773 *carotovora* ssp. *carotovora* 15 (Ecc15) was performed as
1774 previously described.²⁵ Orally treated flies were incubated
1775 at 29°C until dissection for analyses.

1776 1777 *Generation of Genetically Modified Lines of* 1778 *Drosophila*

1779 Esg-Gal4; UAS-GFP, tub-Gal80^{TS} (Esg^{TS}, progenitor spe-
1780 cific)⁵⁵ and Uas lines (BDSC 41137) were used for creating
1781 flies with miR-7 overexpression in Esg stem or progenitor
1782 cells. Genetic crosses for flies containing Gal4-UAS-Gal80
1783 system were crossed using ~15 female flies and 5 males,
1784 and transferred during development in a 12-hour light/dark
1785 18°C incubator. Parental generation was removed after 5
1786 days in the 18°C incubator to control for fly density of the
1787 F1 progeny.

1789 *Immunostaining of Drosophila Midgut*

1790 The excised *Drosophila* midguts were fixed in 4% para-
1791 formaldehyde and washed with 0.1% (w/v) Triton X-100 in
1792 PBS. The samples then incubated for an hour in blocking
1793 solution (1% (w/v) BSA, 1% (v/v) normal donkey serum,
1794 and 0.1% (w/v) Triton X-100 in PBS) followed by overnight
1795 primary antibody incubation and 2 hours secondary anti-
1796 body staining. Primary antibodies used in this study were
1797 rabbit anti-PH3 (1:000; EMD Millipore, Burlington, MA).
1798 Secondary antibodies used in this study were donkey anti-
1799 rabbit-555 (1:2000; Thermo Fisher Scientific). DAPI
1800 (1:50,000) was used to visualize nuclei. Imaging was per-
1801 formed on a Zeiss LSM 700 fluorescent/confocal inverted
1802 microscope. PH3-positive cells were manually counted
1803 along the surface of the midgut.

1804 1805 *Statistics*

1806 In most figure panels, quantitative data are reported as
1807 an average of biological replicates ± SEM. In figure panels
1808 pertaining to bright field bud count analysis and whole-
1809 mount immunofluorescent staining in enteroids, quantita-
1810 tive data are reported as an average of values from all the
1811 enteroids pooled from multiple independent experiments ±
1812 SEM (n = 2–7 wells per condition per experiment). In all
1813 analyses, statistical differences were assessed by 2-tailed
1814 Student *t* test with threshold *P* value <.05, unless other-
1815 wise specifically noted. All authors had access to the study
1816 data and had reviewed and approved the final manuscript.

1817 1818 *References*

- 1820 1. Clevers H. The intestinal crypt, a prototype stem cell
1821 compartment. *Cell* 2013;154:274–284.
- 1822 2. Smith NR, Gallagher AC, Wong MH. Defining a stem cell
1823 hierarchy in the intestine: markers, caveats and contro-
1824 versies. *J Physiol* 2016;594:4781–4790.
- 1825 3. Jadhav U, Saxena M, O'Neill NK, Saadatpour A, Yuan GC,
1826 Herbert Z, Murata K, Shivdasani RA. Dynamic

- 1827 reorganization of chromatin accessibility signatures dur-
1828 ing dedifferentiation of secretory precursors into Lgr5+
1829 intestinal stem cells. *Cell Stem Cell* 2017;21:65–77.e5.
- 1830 4. Yan KS, Gevaert O, Zheng GXY, Anchang B, Probert CS,
1831 Larkin KA, Davies PS, Cheng ZF, Kaddis JS, Han A,
1832 Roelf K, Calderon RI, Cynn E, Hu X, Mandleywala K,
1833 Wilhelmy J, Grimes SM, Corney DC, Boutet SC, Terry JM,
1834 Belgader P, Ziraldo SB, Mikelsen TS, Wang F, von
1835 Furstenberg RJ, Smith NR, CHandrakesan P, May R,
1836 Chrissy MAS, Jain R, Cartwright CA, Niland JC, Hong YK,
1837 Carrington J, Breault DT, Epstein J, Houchen CW,
1838 Lynch JP, Martin MG, Plevritis SK, Curtis C, Ji HP, Li L,
1839 Henning SJ, Wong MH, Kuo CJ. Intestinal enteroendocrine
1840 lineage cells possess homeostatic and injury-inducible
1841 stem cell activity. *Cell Stem Cell* 2017;21:78–90.e6.
- 1842 5. Ivey KN, Srivastava D. MicroRNAs as regulators of dif-
1843 ferentiation and cell fate decisions. *Cell Stem Cell* 2010;
1844 7:36–41.
- 1845 6. Peng Y, Croce CM. The role of MicroRNAs in human
1846 cancer. *Signal Transduct Target Ther* 2016;1:15004.
- 1847 7. Hung YH, Sethupathy P. MicroRNAs in the mammalian
1848 gut endocrine lineage. *Endocrinology* 2018;
1849 159:866–868.
- 1850 8. Latreille M, Hausser J, Stutzer I, Zhang Q, Hastoy B,
1851 Gargani S, Kerr-Conte J, Pattou F, Zavolan M,
1852 Esguerra JL, Eliasson L, Stoffel M. MicroRNA-7a regu-
1853 lates pancreatic beta cell function. *J Clin Invest* 2014;
1854 124:2722–2735.
- 1855 9. Poy MN. MicroRNAs: An adaptive mechanism in the
1856 pancreatic beta-cell...and beyond? *Best Pract Res Clin*
1857 *Endocrinol Metab* 2016;30:621–628.
- 1858 10. Lopez-Beas J, Capilla-Gonzalez V, Aguilera Y,
1859 Mellado N, Lachaud CC, Martin F, Smani T, Soria B,
1860 Hmadcha A. miR-7 modulates hESC differentiation into
1861 insulin-producing beta-like cells and contributes to cell
1862 maturation. *Mol Ther Nucleic Acids* 2018;12:463–477.
- 1863 11. Xu H, Guo S, Li W, Yu P. The circular RNA Cdr1as, via
1864 miR-7 and its targets, regulates insulin transcription and
1865 secretion in islet cells. *Sci Rep* 2015;5:12453.
- 1866 12. Wang Y, Liu J, Liu C, Naji A, Stoffers DA. MicroRNA-7
1867 regulates the mTOR pathway and proliferation in adult
1868 pancreatic beta-cells. *Diabetes* 2013;62:887–895.
- 1869 13. Bravo-Egana V, Rosero S, Molano RD, Pileggi A, Ricordi C,
1870 Dominguez-Bendala J, Pastori RL. Quantitative differential
1871 expression analysis reveals miR-7 as major islet microRNA.
1872 *Biochem Biophys Res Commun* 2008;366:922–926.
- 1873 14. Kredo-Russo S, Mandelbaum AD, Ness A, Alon I,
1874 Lennox KA, Behlke MA, Hornstein E. Pancreas-enriched
1875 miRNA refines endocrine cell differentiation. *Develop-*
1876 *ment* 2012;139:3021–3031.
- 1877 15. Downing S, Zhang F, Chen Z, Tzanakakis ES. MicroRNA-
1878 7 directly targets Reg1 in pancreatic cells. *Am J Physiol*
1879 *Cell Physiol* 2019;317:C366–C374.
- 1880 16. Knudsen LA, Petersen N, Schwartz TW, Egerod KL. The
1881 MicroRNA Repertoire in enteroendocrine cells: identifica-
1882 tion of miR-375 as a potential regulator of the enter-
1883 oendocrine lineage. *Endocrinology* 2015;156:3971–3983.
- 1884 17. Heverhagen AE, Legrand N, Wagner V, Fendrich V,
1885 Bartsch DK, Slater EP. Overexpression of MicroRNA
1886

- 1887 miR-7-5p is a potential biomarker in neuroendocrine 1946
 1888 neoplasms of the small intestine. *Neuroendocrinology* 1947
 1889 2018;106:312–317. 1948
- 1890 18. von Furstenberg RJ, Buczacki SJ, Smith BJ, Seiler KM, 1949
 1891 Winton DJ, Henning SJ. Side population sorting sepa- 1950
 1892 rates subfractions of cycling and non-cycling intestinal 1951
 1893 stem cells. *Stem Cell Res* 2014;12:364–375. 1952
- 1894 19. Richards P, Pais R, Habib AM, Brighton CA, Yeo GS, 1953
 1895 Reimann F, Gribble FM. High fat diet impairs the function 1954
 1896 of glucagon-like peptide-1 producing L-cells. *Peptides* 1955
 1897 2016;77:21–27. 1956
- 1898 20. Mah AT, Van Landeghem L, Gavin HE, Magness ST, 1957
 1899 Lund PK. Impact of diet-induced obesity on intestinal 1958
 1900 stem cells: hyperproliferation but impaired intrinsic 1959
 1901 function that requires insulin/IGF1. *Endocrinology* 2014; 1960
 1902 155:3302–3314. 1961
- 1903 21. Beyaz S, Mana MD, Roper J, Kedrin D, Saadatpour A, 1962
 1904 Hong SJ, Bauer-Rowe KE, Xifaras ME, Akkad A, Arias E, 1963
 1905 Pinello L, Katz Y, Shinagare S, Abu-Remaileh M, 1964
 1906 Mihaylova MM, Lamming DW, Dogum R, Guo G, 1965
 1907 Bell GW, Selig M, Nielsen GP, Gupta N, Ferrone CR, 1966
 1908 Deshpande V, Yuan GC, Orkin SH, Sabatini DM, 1967
 1909 Yilmaz OH. High-fat diet enhances stemness and 1968
 1910 tumorigenicity of intestinal progenitors. *Nature* 2016; 1969
 1911 531:53–58. 1970
- 1912 22. Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. Beta 1971
 1913 cell 5'-shifted isomiRs are candidate regulatory hubs in 1972
 1914 type 2 diabetes. *PLoS One* 2013;8:e73240. 1973
- 1915 23. Liu S, Zhang P, Chen Z, Liu M, Li X, Tang H. MicroRNA-7 1974
 1916 downregulates XIAP expression to suppress cell growth 1975
 1917 and promote apoptosis in cervical cancer cells. *FEBS* 1976
 1918 *Lett* 2013;587:2247–2253. 1977
- 1919 24. Sato T, Vries RG, Snippert HJ, van de Wetering M, 1978
 1920 Barker N, Stange DE, Van Es JH, Abo A, Kujala P, 1979
 1921 Peters PJ, Clevers H. Single Lgr5 stem cells build crypt- 1980
 1922 villus structures in vitro without a mesenchymal niche. 1981
 1923 *Nature* 2009;459:262–265. 1982
- 1924 25. Buchon N, Broderick NA, Poidevin M, Pradervand S, 1983
 1925 Lemaitre B. *Drosophila* intestinal response to bacterial 1984
 1926 infection: activation of host defense and stem cell pro- 1985
 1927 liferation. *Cell Host Microbe* 2009;5:200–211. 1986
- 1928 26. Tsai YH, Czerwinski M, Wu A, Dame MK, Attili D, Hill E, 1987
 1929 Colacino JA, Nowacki LM, Shroyer NF, Higgins PDR, 1988
 1930 Kao JY, Spence JR. A method for cryogenic preservation 1989
 1931 of human biopsy specimens and subsequent 1990
 1932 organoid culture. *Cell Mol Gastroenterol Hepatol* 2018; 1991
 1933 6:218–222.e7. 1992
- 1934 27. Huang C, Zeng X, Jiang G, Liao X, Liu C, Li J, Jin H, 1993
 1935 Zhu J, Sun H, Wu XR, Huang C. XIAP BIR domain sup- 1994
 1936 presses miR-200a expression and subsequently 1995
 1937 promotes EGFR protein translation and anchorage- 1996
 1938 independent growth of bladder cancer cell. *J Hematol* 1997
 1939 *Oncol* 2017;10:6. 1998
- 1940 28. Basak O, Beumer J, Wiebrands K, Seno H, van 1999
 1941 Oudenaarden A, Clevers H. Induced quiescence of 2000
 1942 Lgr5+ stem cells in intestinal organoids enables differ- 2001
 1943 entiation of hormone-producing enteroendocrine cells. 2002
 1944 *Cell Stem Cell* 2017;20:177–190.e4. 2003
- 1945 29. Liu X, Li G, Su Z, Jiang Z, Chen L, Wang J, Yu S, Liu Z. 2004
 Poly(amido amine) is an ideal carrier of miR-7 for
 enhancing gene silencing effects on the EGFR pathway
 in U251 glioma cells. *Oncol Rep* 2013;29:1387–1394.
30. Sun X, Li J, Sun Y, Zhang Y, Dong L, Shen C, Yang L, 1948
 Yang M, Li Y, Shen G, Tu Y, Tao J. miR-7 reverses 1949
 the resistance to BRAF1 in melanoma by targeting 1950
 EGFR/IGF-1R/CRAF and inhibiting the MAPK and 1951
 PI3K/AKT signaling pathways. *Oncotarget* 2016; 1952
 7:53558–53570. 1953
31. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, 1954
 Zavolan M, Heim MH, Stoffel M. MicroRNAs 103 and 107 1955
 regulate insulin sensitivity. *Nature* 2011;474:649–653. 1956
32. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, 1957
 Rorsman P, Zavolan M, Stoffel M. miR-375 maintains 1958
 normal pancreatic alpha- and beta-cell mass. *Proc Natl* 1959
Acad Sci U S A 2009;106:5813–5818. 1960
33. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, 1961
 Hussain MM. MicroRNA-30c reduces hyperlipidemia and 1962
 atherosclerosis in mice by decreasing lipid synthesis and 1963
 lipoprotein secretion. *Nat Med* 2013;19:892–900. 1964
34. Li X, Cassidy JJ, Reinke CA, Fischboeck S, Carthew RW. 1965
 A microRNA imparts robustness against environmental 1966
 fluctuation during development. *Cell* 2009;137:273–282. 1967
35. Gunawardene AR, Corfe BM, Staton CA. Classification 1968
 and functions of enteroendocrine cells of the lower 1969
 gastrointestinal tract. *Int J Exp Pathol* 2011;92:219–231. 1970
36. Beumer J, Artegiani B, Post Y, Reimann F, Gribble F, 1971
 Nguyen TN, Zeng H, Van den Morn M, Van Es JH, 1972
 Clevers H. Enteroendocrine cells switch hormone 1973
 expression along the crypt-to-villus BMP signalling 1974
 gradient. *Nat Cell Biol* 2018;20:909–916. 1975
37. Shivdasani RA. Limited gut cell repertoire for multiple 1976
 hormones. *Nat Cell Biol* 2018;20:865–867. 1977
38. Hutch CR, Sandoval D. The role of GLP-1 in the meta- 1978
 bolic success of bariatric surgery. *Endocrinology* 2017; 1979
 158:4139–4151. 1980
39. Worthington JJ. The intestinal immunoendocrine axis: 1981
 novel cross-talk between enteroendocrine cells and the 1982
 immune system during infection and inflammatory dis- 1983
 ease. *Biochem Soc Trans* 2015;43:727–733. 1984
40. Moran GW, Leslie FC, Levison SE, Worthington J, 1985
 McLaughlin JT. Enteroendocrine cells: neglected players 1986
 in gastrointestinal disorders? *Therap Adv Gastroenterol* 1987
 2008;1:51–60. 1988
41. Zietek T, Rath E. Inflammation meets metabolic disease: 1989
 gut feeling mediated by GLP-1. *Front Immunol* 2016; 1990
 7:154. 1991
42. Formeister EJ, Sionas AL, Lorange DK, Barkley CL, 1992
 Lee GH, Magness ST. Distinct SOX9 levels differentially 1993
 mark stem/progenitor populations and enteroendocrine 1994
 cells of the small intestine epithelium. *Am J Physiol* 1995
Gastrointest Liver Physiol 2009;296:G1108–G1118. 1996
43. Choi I, Chung HK, Ramu S, Lee HN, Kim KE, Lee S, 1997
 Yoo J, Choi D, Lee YS, Aguilar B, Hong YK. Visualization 1998
 of lymphatic vessels by Prox1-promoter directed GFP 1999
 reporter in a bacterial artificial chromosome-based 2000
 transgenic mouse. *Blood* 2011;117:362–365. 2001
44. Bohorquez DV, Chandra R, Samsa LA, Vigna SR, 2002
 Liddle RA. Characterization of basal pseudopod-like 2003
 processes in ileal and colonic PYY cells. *J Mol Histol* 2004
 2011;42:3–13. 2004

- 2005 45. King SL, Mohiuddin JJ, Dekaney CM. Paneth cells
2006 expand from newly created and preexisting cells during
2007 repair after doxorubicin-induced damage. *Am J Physiol*
2008 *Gastrointest Liver Physiol* 2013;305:G151–G162.
2009 46. Gerbe F, Sidot E, Smyth DJ, Ohmoto M, Matsumoto I,
2010 Dardalhon V, Cesses P, Garnier L, Pouzolles M, Brulin B,
2011 Bruschi M, Harcus Y, Zimmermann VS, Taylor N,
2012 Maizels RM, Jay P. Intestinal epithelial tuft cells initiate
2013 type 2 mucosal immunity to helminth parasites. *Nature*
2014 2016;529:226–230.
2015 47. Peck BC, Mah AT, Pitman WA, Ding S, Lund PK,
2016 Sethupathy P. Functional transcriptomics in diverse in-
2017 testinal epithelial cell types reveals robust MicroRNA
2018 sensitivity in intestinal stem cells to microbial status.
2019 *J Biol Chem* 2017;292:2586–2600.
2020 48. Kanke M, Baran-Gale J, Villanueva J, Sethupathy P. miR-
2021 quant 2.0: an expanded tool for accurate annotation and
2022 quantification of MicroRNAs and their isomiRs from small
2023 RNA-sequencing data. *J Integr Bioinform* 2016;13:307.
2024 49. Love MI, Huber W, Anders S. Moderated estimation of
2025 fold change and dispersion for RNA-seq data with
2026 DESeq2. *Genome Biol* 2014;15:550.
2027 50. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C,
2028 Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast
2029 universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21.
2030 51. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C.
2031 Salmon provides fast and bias-aware quantification
2032 of transcript expression. *Nat Methods* 2017;14:
2033 417–419.
2034 52. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV,
2035 Clark NR, Ma'ayan A. Enrichr: interactive and collabora-
2036 tive HTML5 gene list enrichment analysis tool. *BMC*
2037 *Bioinformatics* 2013;14:128.
2038 53. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF,
2039 Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM,
2040 Lachmann A, McDermott MG, Monteiro CD,
2041 Gundersen GW, Ma'ayan A. Enrichr: a comprehensive
2042 gene set enrichment analysis web server 2016 update. *2064*
2043 *Nucleic Acids Res* 2016;44:W90–W97. *2065*
2044 54. Gonzalez LM, Williamson I, Piedrahita JA, Blikslager AT,
2045 Magness ST. Cell lineage identification and stem cell
2046 culture in a porcine model for the study of intestinal
2047 epithelial regeneration. *PLoS One* 2013;8:e66465. *2068*
2048 55. Micchelli CA, Perrimon N. Evidence that stem cells reside
2049 in the adult *Drosophila* midgut epithelium. *Nature* 2006;
2050 439:475–479. *2070*
2051 *2071*
2052 *2072*
2053 *2073*
2054 *2074*
2055 **Received August 14, 2019. Accepted November 7, 2019.** *2075*
2056 **Correspondence** *2076*
2057 Address correspondence to: Praveen Sethupathy, Department of Biomedical
2058 Sciences, Cornell University, 223 Brooktondale Road, Ithaca, NY 14817.
2059 e-mail: pr46@med.unc.edu; fax: ●●●. *2077*
2060 **Acknowledgments** *Q12*
2061 The authors would like to thank members of the Sethupathy laboratory and
2062 Susan Henning for helpful comments and feedback at various stages of the
2063 study, Dr Richard Blumberg for permission to use the Defa6-Cre-tdTomato
2064 mice in this study, Dr Zhao Li and the Greehey Children's Cancer Research
2065 Institute at University of Texas Health Science Center at San Antonio for
2066 small RNA library preparation and sequencing, Dr Jen Grenier and the
2067 Cornell RNA sequencing core facility for RNA sequencing, the Cornell
2068 University and UNC Chapel Hill Flow Cytometry Core Facilities, and the
2069 Cornell University East Campus Mouse Research Facility. *Q3*
2070 **Conflicts of interest** *2080*
2071 The authors disclose no conflicts. *2081*
2072 **Funding** *2082*
2073 This work was supported by a Pathway to Stop Diabetes Research Accelerator
2074 (1-16-ACE-47 ADA) (to Praveen Sethupathy), the Empire State Stem Cell Fund
2075 (C30293GG) (to Yu-Han Hung), the National Science Foundation (IOS-1656118
2076 and IOS-1653021) (to Nicolas Buchon), the National Institute of Diabetes and
2077 Digestive and Kidney Diseases/National Institutes of Health (U01DK103141
2078 [to Jason R. Spence] and R01DK100508 [to Christopher M. Dekaney]), the
2079 National Institute of Allergy and Infectious Diseases/National Institutes of
2080 Health (U19AI116482) (to Jason R. Spence), project grants from the
2081 European Association for the Study of Diabetes and JDRF (to Gavin A.
2082 Bewick), a Special Emphasis Research Career Award from the National
2083 Institutes of Health (K01OD019911-01A1) (to Liara M. Gonzalez), and the
2084 National Institute on Aging/National Institutes of Health (R01AG041198) (to
2085 Shengli Ding). *2086*
2086 *2087*
2087 *2088*
2088 *2089*
2089 *2090*
2090 *2091*
2091 *2092*
2092 *2093*
2093 *2094*
2094 *2095*
2095 *2096*
2096 *2097*
2097 *2098*
2098 *Q7*2099
2099 *2100*
2100 *2101*
2101 *2102*
2102 *2103*
2103 *2104*
2104 *2105*
2105 *2106*
2106 *2107*
2107 *2108*
2108 *2109*
2109 *2110*
2110 *2111*
2111 *2112*
2112 *2113*
2113 *2114*
2114 *2115*
2115 *2116*
2116 *2117*
2117 *2118*
2118 *2119*
2119 *2120*
2120 *2121*
2121 *2122*